Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term.

The FDA has accepted for review the NDA for bumetanide nasal spray for edema associated with CHF, as well as hepatic and renal disease.

A scientific statement has been published by the AHA regarding obstetric and cardiovascular risk in patients receiving assisted reproductive technology.

In patients with high comorbidity burden that receive EVT for MCA medium-vessel occlusion there are worse clinical outcomes.

The COVID-19 vaccine confers protection against the development of post-COVID-19 conditions, particularly during the Delta and Omicron eras.

Machine learning models may be able to identify women with severe subjective cognitive decline (SCD) during the menopause transition.

Increased intermuscular fat is associated with coronary microvascular dysfunction (CMD) and adverse cardiovascular outcomes.

Underweight pregnancy was associated with lower risk for postpartum hemorrhage but higher risks for adverse neonatal outcomes.

The severity of left ventricular diastolic dysfunction affects risk for incident stroke and transient ischemic attack, as well as major bleeding.

Paxlovid vs placebo reduced COVID-19-related hospitalization and death due to any cause through 28 days, as well as the duration of COVID-19 symptoms.

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

Patients diagnosed with more advanced breast cancer are more likely to have cardiovascular disease, a large study suggests.